title: Peripheral administration of a μ-opioid receptor agonist DAMGO suppresses the anxiolytic and stimulatory effects of caffeine.
abstract: We studied the possibility of modulation of the stimulatory and anxiolytic effects of caffeine by activation of μ-opioid receptors in the gastrointestinal tract. Caffeine in a dose of 10 mg/kg (but not in a dose of 100 mg/kg) had a strong anxiolytic and psychostimulant effect. This effect was manifested in a significant increase in the time spent in the open arms of the elevated plus-maze, elevation of locomotor activity, and stimulation of metabolism. Administration of DAMGO to animals receiving caffeine in a dose of 10 mg/kg abolished the anxiolytic and psychostimulant effects of caffeine. By contrast, administration of DAMGO to rats receiving caffeine in a dose of 100 mg/kg had the anxiolytic effect. Activation of peripheral μ-opioid receptors is followed by the inhibition of the central μ-opioid system. We observed a decrease in the number of μ-opioid receptors in the midbrain and cerebral cortex and inhibition of β-endorphin release from nerve ending of the cingulate cortex in rats. These changes are probably followed by activation of the adenosine system in the brain. Caffeine dose should be increased to achieve the effect. Therefore, the anxiolytic and stimulatory effects of caffeine in a dose of 10 mg/kg are abolished under these conditions. By contrast, the anxiolytic effect of caffeine in a dose of 100 mg/kg (not observed under normal conditions) develops after this treatment.
authors.affiliation: P. K. Anokhin Research Institute of Normal Physiology, Moscow, Russia, s-sudakov@nphys.ru.
authors.forename: S K
authors.initials: SK
authors.lastname: Sudakov
authors.forename: G A
authors.initials: GA
authors.lastname: Nazarova
authors.forename: E V
authors.initials: EV
authors.lastname: Alekseeva
authors.forename: A A
authors.initials: AA
authors.lastname: Kolpakov
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D002110:Caffeine / Q000494:pharmacology*; D002153:Calorimetry, Indirect; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology*; D018782:Maze Learning / Q000187:drug effects; D008636:Mesencephalon / Q000187:drug effects / Q000378:metabolism; D009043:Motor Activity / Q000502:physiology; D051381:Rats; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism*
chemical_list: D014151:Anti-Anxiety Agents; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D002110:Caffeine